Funding for this research was provided by:
University of Melbourne (McKenzie Postdoctoral Fellowship)
Saving Lives at Birth (AID-OAA-F-17-00012)
Received: 27 January 2020
Accepted: 7 June 2020
First Online: 28 July 2020
Ethics approval and consent to participate
: Ethical clearance for the primary and secondary data collection required to inform development of the model was obtained from the Human Research Ethics Committee of the University of Melbourne (Ethics ID: 1749798.1).
: Not applicable.
: VLO, PL and MPM are part of a product development team at Monash University, which is developing an inhaled heat stable oxytocin product for the prevention of PPH in resource-poor settings.MPM is the co-inventor of a worldwide patent application ‘Method and Formulation for Inhalation’ (WO 2013/016754) that covers the delivery of biologically active agents (including oxytocin) in the form of dry powders for inhalation. The authors have no commercial interest in the outcomes of this study or the introduction of the inhaled oxytocin product in LMICs.All other authors declare no other competing interests.